ZNTL: Zentalis Pharmaceuticals, Inc. Company Value to Net Income

Zentalis Pharmaceuticals, Inc. - graphic logo of issuer ZNTL

This Zentalis Pharmaceuticals (ZNTL) market price chart on the GURU.Markets platform, where the P/E ratio is -1.00, illustrates the biotech company's efforts to develop selective WEE1 inhibitors to combat resistant tumors. The business faces fierce competition for patents and the risk of low-cost biosimilars emerging. Meanwhile, operational stability is ensured by US jurisdiction and the international status of its medical research.

P/E Multiple: Zentalis Pharmaceuticals (ZNTL) for 07/04/2022 - 11/18/2026

Comprehensive metric breakdowns and analytics for zentalis.com (ZNTL)

- share price and consensus valuation forecast:
Summary company analysis:ZNTL (Zentalis Pharmaceuticals, Inc.)
Product sample of Zentalis Pharmaceuticals

Assessing the investment reliability of equity assets begins with analyzing the business payback period via the ratio of market capitalization to net income. For Zentalis Pharmaceuticals (ZNTL), whose oncology developments remain independent of macroeconomic cycles, the company's P/E ratio dynamics allow investors to filter out market noise and determine the fair value of shares, accounting for their dependence on venture capital inflows.